The deubiquitinase USP35 relieves neuronal ferroptosis caused by spinal cord injury by stabilizing NRF2 expression
Аннотация
Neuronal ferroptosis is closely related to spinal cord injury (SCI). As a member of the deubiquitinase family, ubiquitin‑specific peptidase 35 (USP35) has been confirmed to inhibit ferroptosis, but whether it is involved in the regulation of ferroptosis in SCI remains unclear. The aim of this study was to explore the regulatory effect and molecular mechanism of USP35 on SCI-induced neuronal ferroptosis. In this study, an Erastin-induced ferroptosis phenotype model was constructed in PC12 cells to elucidate the molecular mechanism of neuronal ferroptosis, and an impact-induced rat model of SCI was used for in vivo validation. Hematoxylin and eosin (HE) staining and Nissl staining were used to detect pathological changes in the spinal cord tissue and neuronal injury. Changes in ferroptosis-related indicators were evaluated using kits and western blotting. The interaction between USP35 and nuclear factor erythroid 2-related factor 2 (Nrf2) was verified by coimmunoprecipitation. The result shows that USP35 expression was low in Erastin-induced PC12 cells and spinal cord tissues from SCI rats. Overexpression of USP35 attenuated ferroptosis by reducing Fe²⁺ accumulation, reactive oxygen species (ROS) production, and acyl-CoA synthetase long-chain family member 4 (ACSL4) expression, as well as by upregulating the expression of glutathione (GSH), ferritin heavy chain 1 (FTH1), and glutathione peroxidase 4 (GPX4). In addition, USP35 overexpression significantly improved histopathological injury and partially restored neuronal loss in the spinal cords of SCI rats. Mechanistically, NRF2 expression was reduced in Erastin-treated PC12 cells, and USP35 overexpression maintained NRF2 stability through deubiquitination. However, NRF2 silencing significantly diminished the suppressive effect of USP35 overexpression on Erastin-induced ferroptosis. Overall, USP35 stabilizes NRF2 protein expression via the deubiquitination of NRF2, thereby suppressing neuronal ferroptosis and alleviating SCI. These findings reveal a novel deubiquitination‑dependent regulatory mechanism of ferroptosis after SCI and provide a potential molecular target for the development of neuroprotective therapeutic strategies against spinal‑cord‑injury‑induced neuronal damage.